MedTrace Logo

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-05-08

No results posted yet for this study

Summary

Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of the study). Based on the long-term observation after CoRaLa I study an importantly shorter duration of treatment and a relevant reduction of the total number of re-injections in RL patients is expected.

Conditions

  • Central Retinal Vein Occlusion With Macular Edema

Interventions

DRUG

Ranibizumab Injection

initial three injections of Ranibizumab - afterwards pro re nata monthly

DEVICE

Laser photocoagulation

Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times

Sponsors & Collaborators

  • University of Leipzig

    collaborator OTHER

  • University of Giessen

    lead OTHER

Principal Investigators

  • Matus Rehak, Professor · Department of Ophthalmology Justus-Liebig-Universität Giessen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04444492 on ClinicalTrials.gov